In this article, we will look at the 13 Best Long-Term Penny Stocks to Buy According to Analysts.

What are the Fed’s Plans for 2025?

On June 18, Société Générale’s Subadra Rajappa appeared on CNBC to talk about her expectations from the Fed. She said that the Fed is likely to give the market two rate cuts this year: one in September and another in December. She also stated that she doesn’t expect a change in the median dot for the year, but some other changes may emerge.

These may include inflation rising slightly higher, employment rates also slightly higher, and growth a tad lower for this year. Overall, she expects it to be in line with what the market is pricing for this year, retaining the call for two rate cuts in 2025 and perhaps 100 basis points for cuts.

READ ALSO: 11 Cheap Gold Stocks to Buy According to Hedge Funds and 13 Crypto Stocks with the Highest Upside Potential.

Wells Fargo’s Paul Christopher also commented on the situation, stating that when circumstances are cloudy, it is best to stay near one’s umbrella and landmarks, which in this case are the tariffs that are coming, and some of that pricing is already being reflected in goods. He projects only one rate cut this year, as inflation in the second half of the year is likely to give the Fed some pause.

With these trends in view, let’s look at the 13 best long-term penny stocks to buy according to analysts.

Our Methodology

We used the Finviz stock screener to compile a list of penny stocks (stocks with a price below $5) that analysts were bullish on and that had at least five analysts covering them. We then chose the top 13 with the highest upside potential and also added the number of hedge fund holders for each stock as of Q1 2025. We sourced the hedge fund data from Insider Monkey’s database. The list is arranged in ascending order of analyst upside.

Note: All data was sourced on June 20.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

13 Best Long-Term Penny Stocks to Buy According to Analysts

13. Opko Health Inc. (NASDAQ:OPK)

Stock Price: $1.29

Analyst Upside: 132.56%

Number of Hedge Fund Holders: 26

Opko Health Inc. (NASDAQ:OPK) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. In a report released on May 2, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK) with a price target of $3.00. The rating update followed the company’s announcement of its fiscal Q1 2025 results, which included significant developments.

These included the sale of its BioReference laboratory testing businesses, which focused on oncology and oncology-related clinical testing services, for up to $225 million. The transaction includes a $192.5 million payout at closing and up to $32.5 million in a performance-based earnout.

Opko Health Inc. (NASDAQ:OPK) also announced a collaboration agreement with Entera Bio to advance oral GLP-1/glucagon tablet candidates into the clinic for the treatment of metabolic disorders and obesity. ModeX is also continuing advancements in its immuno-oncology and immunology portfolio, with a pipeline showing the progress of four potential clinical candidates.

Opko Health Inc. (NASDAQ:OPK) is a biopharmaceutical and diagnostics company that provides healthcare services. Its operations are divided into the Diagnostics and Pharmaceuticals segments.

12. MannKind Corporation (NASDAQ:MNKD)

Stock Price: $3.81

Analyst Upside: 136.22%

Number of Hedge Fund Holders: 29

MannKind Corporation (NASDAQ:MNKD) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 19, analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on MannKind Corporation (NASDAQ:MNKD), reducing the price target to $7 from $9. Despite some near-term uncertainties, the analyst based the rating on the company’s long-term growth, stating that the stock is currently undervalued.

Calling the company a unique player in the SMID-cap biotech sector, the analyst stated that MannKind Corporation (NASDAQ:MNKD) holds an optimistic position because of its modest Afrezza sales and cash flow positive status from Tyvaso DPI royalties. The company is also focusing on inhaled therapies for orphan respiratory indications, which further presents several opportunities for success, according to the analyst.

While Khurshid acknowledged the risks associated with the Tyvaso DPI royalty stream, especially with Yutrepia’s recent approval and position as a competitor, he also expressed near-term optimism about the commercial trajectory of Tyvaso DPI and its potential effect on the company’s financials. The analyst considers the upcoming results from the Phase 3 TETON-2 trial of Tyvaso in IPF to be a notable catalyst for the MannKind Corporation (NASDAQ:MNKD).

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases. The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.